| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
5-Iminodaunorubicin targets DNA in cancer cells. As an anthracycline, it intercalates into DNA and inhibits topoisomerase II, preventing DNA replication and transcription. The compound induces concealed DNA strand breaks within cancer cells, mediated by protein interactions. It is a quinone-modified anthracycline.
|
|---|---|
| ln Vitro |
5-Iminodaunorubicin causes protein-concealed DNA strand breaks in murine leukemia L1210 cells. Apposed single-strand breaks, or double-strand breaks, may be the source of many 5-iminodaunorubicin breaks[2].
5-Iminodaunorubicin is a quinone-modified anthracycline that retains antitumor activity. It induces DNA strand breaks in cancer cells. The compound's quinone modification is designed to enhance anticancer activity while potentially reducing cardiotoxicity compared to parent anthracyclines. |
| ln Vivo |
5-Iminodaunorubicin (5-ID; 1–16 mg/kg) therapy widens the QRS complex, raises the voltage of the R- and S-waves, and lengthens the Q alpha T interval in rats. Additionally, 5-Iminodaunorubicin suppresses the quinone redox cycle. 5-Iminodaunorubicin exhibits reduced cardiotoxicity [1].
5-Iminodaunorubicin has been evaluated in preclinical studies for its antitumor activity. As an anthracycline derivative, it is expected to show activity against a range of cancers. Specific in vivo efficacy data and dosing regimens are not extensively detailed in standard reference sources. |
| Enzyme Assay |
5-Iminodaunorubicin's DNA binding and topoisomerase II inhibition can be assessed using in vitro biochemical assays. DNA intercalation is measured using fluorescence spectroscopy or gel mobility shift assays. Topoisomerase II activity is assessed by measuring relaxation of supercoiled DNA in the presence of varying concentrations of the compound.
|
| Cell Assay |
The cellular activity of 5-iminodaunorubicin is evaluated in cancer cell lines. Cells are treated with increasing concentrations of the compound, and cell viability is assessed using MTT or CellTiter-Glo assays. DNA strand breaks are measured using the comet assay or γ-H2AX staining. The compound's ability to induce apoptosis is also assessed.
|
| Animal Protocol |
5-Iminodaunorubicin would be evaluated in animal models of cancer, such as xenograft models. The compound would be administered via intravenous or intraperitoneal routes at various doses. Tumor growth inhibition, survival, and cardiotoxicity parameters would be monitored to assess efficacy and safety.
|
| ADME/Pharmacokinetics |
5-Iminodaunorubicin hydrochloride has a molecular formula of C27H31ClN2O9 and a molecular weight of 563.00. It is a quinone-modified anthracycline. Specific pharmacokinetic parameters such as half-life, bioavailability, and plasma protein binding are not extensively detailed in standard reference sources.
|
| Toxicity/Toxicokinetics |
5-Iminodaunorubicin is designed to potentially reduce cardiotoxicity compared to parent anthracyclines. As an anthracycline, it may still cause myelosuppression, gastrointestinal effects, and other anthracycline-related toxicities. Specific LD50 values and organ-specific toxicity data are not extensively detailed.
|
| References |
|
| Additional Infomation |
5-Iminodaunorubicin hydrochloride (CAS# 67324-99-6) is a quinone-modified anthracycline that retains antitumor activity. It is structurally related to daunorubicin and is designed to enhance anticancer activity while potentially reducing cardiotoxicity. The compound induces DNA strand breaks in cancer cells.
|
| Molecular Formula |
C27H31CLN2O9
|
|---|---|
| Molecular Weight |
563.00
|
| Exact Mass |
562.172
|
| CAS # |
67324-99-6
|
| Related CAS # |
5-Iminodaunorubicin;72983-78-9
|
| PubChem CID |
72399
|
| Appearance |
Purple to black solid powder
|
| Density |
1.51g/cm3
|
| Boiling Point |
864.9ºC at 760 mmHg
|
| Flash Point |
476.9ºC
|
| Index of Refraction |
1.698
|
| LogP |
2.816
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
39
|
| Complexity |
963
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=N)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl
|
| InChi Key |
BLLIIPIJZPKUEG-HPTNQIKVSA-N
|
| InChi Code |
InChI=1S/C27H30N2O9/c1-10-23(31)14(28)7-17(37-10)38-16-9-27(35,11(2)30)8-13-19(16)26(34)20-21(25(13)33)24(32)12-5-4-6-15(36-3)18(12)22(20)29/h4-6,10,14,16-17,23,29,31,33-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,23+,27-/m0/s1
|
| Chemical Name |
(8S,10S)-8-acetyl-10-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,8,11-trihydroxy-12-imino-1-methoxy-9,10-dihydro-7H-tetracen-5-one
|
| Synonyms |
5-Iminodaunorubicin hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~230 mg/mL (~408.5 mM)
H2O : ~8.3 mg/mL (~14.8 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (8.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7762 mL | 8.8810 mL | 17.7620 mL | |
| 5 mM | 0.3552 mL | 1.7762 mL | 3.5524 mL | |
| 10 mM | 0.1776 mL | 0.8881 mL | 1.7762 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
